Some further selling today, I honestly thought 1c would be a solid base, looks like a retest of the recent lows may be coming, I'm not really expecting any news until the new year anyhow Glyndwr let's assume trials are progressing well but many more unanswered questions, what will be the cost for Lilly? Will it be an annual subscription or a monthly fee? How quickly will Lilly produce an SOA? Has Lilly got the capability to produce difficult SOAs or does it only produce simple SOAs? Will Lilly meet FPs dear groups compliance requirements? and the most important question is what is the quintessential characteristic that Lilly has over its competitors and what are the benefits to FPs?
Ann: Intiger Market Update, page-1023
-
- There are more pages in this discussion • 270 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CF1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.86M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 250000 | 2.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 301058 | 3 |
View Market Depth
| Last trade - 16.12pm 13/11/2024 (20 minute delay) ? |
| CF1 (ASX) Chart |
Day chart unavailable